Final text for addition to The International Pharmacopoeia
Manufacture. Kanamycin monosulfate is produced by methods of manufacture designed to eliminate or minimize substances lowering blood pressure. The method of manufacture is validated to demonstrate that the product, if tested, would comply with the test as described under 3.7 Undue toxicity, using 0.5 ml of a solution containing 2 mg per ml.
Get Price